Hangzhou Jiuyuan Gene Engineering Raises HK$485 Million from IPO Ahead of Hong Kong Trading Debut

MT Newswires Live11-28

Hangzhou Jiuyuan Gene Engineering (HKG:2566) raised about HK$485.4 million in net proceeds from its Hong Kong initial public offering after pricing the shares near the upper limit of its indicative price range.

The biotechnology firm issued 45,398,800 shares at HK$12.42 apiece, with the low end of its guidance of HK$11.48 and the high end of HK$12.56 each, according to a Wednesday disclosure.

The deal's Hong Kong or public offering portion was 675.83x oversubscribed, prompting the company to issue about 22.7 million shares, more than the 4.5 million shares originally allotted.

The international or placing shares were 1.18x oversubscribed, and the firm issued about 22.7 million shares.

Hangzhou Jiuyuan Gene Engineering will start trading on the Hong Kong bourse today, Nov. 28.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment